研究单位：[1]Allergan[2]Beijing Hospital,Beijing,China,100005[3]Xuanwu Hospital Capital Medical University,Beijing,China,100053[4]Peking University Third Hospital,Beijing,China,100191[5]Beijing Tongren hospital Capital Medical University,Beijing,China,100730[6]Zhongshan Ophthalmic Center, Sun Yat-Sen University,Guangzhou,Guangdong,China,510060[7]Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology,Wuhan,Hubei,China,430030[8]Second Xiangya Hospital of Central South University,Changsha,Hunan,China,410011[9]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[10]Eye & ENT Hospital of Fudan University,Shanghai,Shanghai,China,200031[11]West China Hospital, Sichuan University,Chengdu,Sichuan,China,610041[12]Tianjin Eye Hospital,Tianjin,China,300020[13]Tianjin Medical University Eye Hospital,Tianjin,China,300384[14]The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310009[15]Eye Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,China,325027[16]Henan Provincial Eye Hospital,Henan,Zhengzhou,China,450003
研究目的：
A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blocker or prostaglandin analogues.
